MCL Literature Feed

This case report of an 80-year-old man with MCL presenting with severe hyperleukocytosis (>491x10^9/L) highlights the diagnostic challenge of differentiating this rare presentation from other leukemias.

In elderly, frontline MCL, this SHINE secondary analysis shows achieving a complete response is critical for long-term PFS, and adding ibrutinib to BR significantly increases CR rates.

This case report highlights the risk of life-threatening invasive aspergillosis in an elderly MCL patient with chronic neutropenia, underscoring the need for high clinical suspicion for fungal infections.

This phase II trial protocol compares chemo-free ibrutinib/venetoclax/rituximab versus ibrutinib-chemoimmunotherapy in treatment-naive elderly MCL, aiming to establish a new frontline standard.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

A case report highlights chylothorax as a rare clinical presentation of mantle cell lymphoma, underscoring the need to consider malignancy in the differential diagnosis of this condition.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

This case report of sequential follicular lymphoma, MCL, and CML highlights the long-term risk of subsequent malignancies and severe infections (COVID-19-induced HLH) following repeated immunochemotherapy.

This first reported case of composite MCL and T-cell prolymphocytic leukemia highlights the diagnostic challenge of co-existing lymphoid malignancies, where an indolent T-PLL clone was present for years before diagnosis.

The MCL35 gene expression assay identifies high-risk older patients who do not benefit from adding ibrutinib to bendamustine-rituximab, mandating alternative frontline strategies for this molecularly-defined subgroup.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

This review advocates for adding a BTKi to frontline immunochemotherapy for transplant-eligible patients as a new standard of care, while also summarizing its emerging role in older patients.

This case report of synchronous gastric adenocarcinoma and mantle cell lymphoma highlights the need for thorough pathological evaluation of surgical specimens, as MCL can be an incidental finding.

This study compares bendamustine-rituximab (BR) versus R-CHOP as initial therapy for transplant-ineligible MCL patients, providing evidence to guide frontline treatment selection in this common clinical setting.

In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.

This case report of primary colonic MCL presenting with intussusception highlights surgery's crucial role in diagnosis and managing complications for rare, localized extranodal disease before systemic therapy.

This case report describes a rare paraneoplastic syndrome in MCL causing severe thrombocytopenia via both bone marrow failure and immune destruction, which responded to lymphoma-directed chemoimmunotherapy but not standard ITP treatment.

This case of clonally-related composite DLBCL and CD5-negative MCL highlights a rare diagnostic challenge, emphasizing the need for comprehensive IHC panels to avoid misdiagnosing transformed lymphoma.

Ibrutinib monotherapy rapidly resolved bilateral intraocular MCL recurrence presenting as pseudo-uveitis and glaucoma, demonstrating its efficacy in this rare CNS sanctuary site relapse.

In previously untreated, transplant-ineligible MCL, achieving MRD-negativity after bendamustine-obinutuzumab induction allows for the safe omission of maintenance therapy without worsening progression-free survival.

This review highlights using geriatric assessments to guide therapy selection and proactively manage toxicities in older MCL patients, aiming to optimize outcomes and avoid over- or undertreatment.

This case report demonstrates CNS relapse in an MCL patient with a low Ki-67 (10%), underscoring the need for CSF analysis in symptomatic patients regardless of proliferation index.

This SEER database analysis confirms older age and advanced stage interact to worsen survival, while also identifying widowed marital status as an independent predictor of higher mortality in MCL.

This case report demonstrates that MCL can rarely cause membranous nephropathy, a severe renal complication that can be fully resolved by successfully treating the underlying lymphoma with chemotherapy.

This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.

A case report of an elderly MCL patient with sequential relapses in rare extranodal sites (ocular adnexa, soft tissue, heart) highlights the need for vigilance for unusual disease presentations.

This large retrospective study of 476 MCL patients aged ≥80 provides crucial real-world outcome data, informing treatment selection and expectations in the very elderly population.

This case report describes a rare MCL CNS relapse presenting as Horner syndrome and oculomotor nerve palsy, highlighting the need for CSF analysis in patients with atypical neurological symptoms, even with normal imaging.

This case report demonstrates that MCL can cause severe renal failure via both direct infiltration and paraneoplastic glomerulonephritis, underscoring the need for kidney biopsy in unexplained nephropathy.